Dr Reddy’s receives two USFDA observations for New York API facility
Dr Reddy’s Laboratories announced on Saturday that the United States Food and Drug Administration (USFDA) has issued a Form 483 with two observations following an inspection of its API (Active Pharmaceutical Ingredients) manufacturing facility in Middleburgh, New York.In a regulatory filing, the Hyderabad-based pharmaceutical company stated that the GMP (Good Manufacturing Practice) inspection was carried…